Special items: Ovarian Cancer and Us blog best viewed in Firefox

Thursday, June 10, 2010

ASCO: (Farletuzumab) Antibody Shows Promise in Ovarian Cancer

"The phase II clinical trial evaluated responses in 44 ovarian cancer patients in their first relapse period, who received either farletuzumab as a single agent or in combination with carboplatin and a taxane..."cont'd

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.